1
|
Infliximab in Recalcitrant Severe Atopic Eczema Associated with Contact Allergy. Int J Immunopathol Pharmacol 2018. [DOI: 10.1177/205873920601900125] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Infliximab is an anti-tumour necrosis factor (TNF)-alpha chimeric monoclonal antibody which is effective in diseases associated with a T-helper (Th) 1 response, such as rheumatoid arthritis, Crohn's disease and psoriasis. There are sporadic case reports of atopic dermatitis (AD) induced or precipitated by anti-TNF-alpha therapy, which have been attributed to the switch towards Th2-mediated reactions. We report the case of a 30-year-old man with long-standing severe AD associated with contact allergy and poorly responding to conventional treatments. The use of infliximab resulted in a dramatic amelioration of AD lesions and pruritus, persisting at follow-up examinations over a 3-year period. Probably, the unexpected response to infliximab therapy in this case might be due to some peculiar features of AD in our patient (i.e. chronic-continuous course and concomitant contact allergy) which could have been responsible for a more preponderant recruitment of Th1 cells as compared to “common” forms of AD.
Collapse
|
2
|
Frydas S, Karagouni E, Hatzistilianou M, Kempuraj D, Comani S, Petrarca C, Iezzi T, Verna N, Conti P, Castellani ML. Cytokines and Allergic Disorders: Revisited Study. Int J Immunopathol Pharmacol 2016; 17:233-5. [PMID: 15461856 DOI: 10.1177/039463200401700302] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
3
|
Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy withDermatophagoides farinaedrops in patients with atopic dermatitis. Int J Dermatol 2013; 53:650-5. [PMID: 23968339 DOI: 10.1111/ijd.12302] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Yu-E Qin
- International Health Care Center; First Affiliated Hospital; College of Medicine; Zhejiang University; Hang Zhou China
| | - Jing-Ran Mao
- Department of Dermatology; The First Affiliated Hospital; College of Medicine; Zhejiang University; Hang Zhou China
| | - Yue-chan Sang
- Department of Clinical Sciences; Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.; Shanghai China
| | - Wen-Xiu Li
- Department of Clinical Sciences; Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.; Shanghai China
| |
Collapse
|
4
|
Marcucci F, Incorvaia C, Sensi L, Di Cara G, Cadario G, Cavaliere A, Moingeon P, Puccinelli P, Di Gioacchino M, Frati F. Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol 2008; 21:609-13. [PMID: 18831928 DOI: 10.1177/039463200802100314] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The cells involved in allergic inflammation, such as mast cells, basophils, and eosinophils, have been thoroughly studied in the nose, the lungs and the skin, demonstrating an evident increase in response to the introduction of the specific allergen, while little is known in the mucosal system and particularly in the oral mucosa. We investigated such tissue by using the model of sublingual immunotherapy (SLIT), by which high doses of the specific allergen enter the mouth. Oral biopsies were carried out on seven subjects allergic to grass pollen and treated with SLIT by a grass extract. In biopsies carried out before SLIT there was a very low number of mast cells and eosinophils both in the epithelium and subepithelium layers, and insignificant changes were detected after SLIT. These findings show the lack of allergic inflammation in the oral mucosa upon contact with the specific allergen and confirm the role of the mouth as a tolerogenic site, which is conceivable considering the different attitude of the mouth, where the antigens transit to undergo digestion, in respect to the airways or the skin, where the antigen absorption is potentially dangerous.
Collapse
Affiliation(s)
- F Marcucci
- Pediatrics, University Department of Medical and Surgical Specialties and Public Health, Perugia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Saporta D. Sublingual immunotherapy: a novel, albeit not so new, immunotherapy treatment modality. ACTA ACUST UNITED AC 2008; 22:253-7. [PMID: 18211743 DOI: 10.2500/ajr.2008.22.3131] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Specific allergy immunotherapy traditionally has been thought of as subcutaneous injection immunotherapy (SCIT). There also are noninjection routes for the administration of immunotherapy. The best-known and studied of these noninjection routes is the sublingual route, usually known as sublingual immunotherapy (SLIT). SLIT has been in use for many decades; however, to this date, it is not well known to the majority of allergy practitioners in this country. The purpose of this study is to help change this perception so that SLIT eventually can be considered one more tool in the allergist's armamentarium. METHODS A literature review was performed. It included articles from the early American clinicians and present publications that are mostly of European origin. RESULTS It will become clear to the reader that the key features of SLIT are its efficacy, great safety, and simplicity of administration. CONCLUSION SLIT is a safe treatment modality that should be considered as a useful additional tool in the therapeutic armamentarium.
Collapse
Affiliation(s)
- Diego Saporta
- Private practice, Elizabeth, New Jersey 07208, USA. allergydropsnj.com
| |
Collapse
|
6
|
Saporta D, McDaniel AB. Efficacy Comparison of Multiple-Antigen Subcutaneous Injection Immunotherapy and Multiple-Antigen Sublingual Immunotherapy. EAR, NOSE & THROAT JOURNAL 2007. [DOI: 10.1177/014556130708600816] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
We performed an observational study to determine whether allergen-specific sublingual immunotherapy (SLIT) is as effective as allergen-specific subcutaneous injection immunotherapy (SCIT). Our study population was comprised of 66 patients who had been taking SLIT. Of this group, 36 patients had switched to SLIT after having been treated with SCIT (group I), while the remaining 30 patients had received SLIT only (group II). A questionnaire was used to evaluate the results of treatment. In group I, 33 patients (92%) gave SLIT a favorable rating; 27 of these patients (75%) said it was just as effective as SCIT, and 6 (17%) said it was actually superior (the remaining 3 patients [8%] said that SCIT was better). In group II, 27 of 30 patients (90%) said they had attained symptom relief with SLIT; 21 (70%) said that the relief had been very significant. Overall, 60 of the 66 patients (91 %) expressed various degrees of satisfaction with SLIT. We believe that our SLIT protocol, which is based on established guidelines for SCIT administration, is an effective, safe, well-tolerated, and easy-to-use regimen. Future prospective studies of larger groups are clearly indicated.
Collapse
Affiliation(s)
- Diego Saporta
- Otolaryngic allergists in private practice in Elizabeth, N.J., and New Albany, Ind., respectively
| | - Alan B. McDaniel
- Otolaryngic allergists in private practice in Elizabeth, N.J., and New Albany, Ind., respectively
| |
Collapse
|
7
|
Abstract
The incidence of allergic rhinitis has been increasing for the last few decades, in keeping with the rising incidence of atopy worldwide. Allergic rhinitis has a prevalence of up to 40% in children, although it frequently goes unrecognized and untreated. This can have enormous negative consequences, particularly in children, since it is associated with numerous complications and comorbidities that have a significant health impact on quality of life. In fact, allergic rhinitis is considered to be a risk factor for asthma. There are numerous signs of allergic rhinitis, particularly in children, that can alert an observant clinician to its presence. Children with severe allergic rhinitis often have facial manifestations of itching and obstructed breathing, including a gaping mouth, chapped lips, evidence of sleep deprivation, a long face, dental malloclusions, and the allergic shiner, allergic salute, or allergic crease. The medical history is extremely important as it can reveal information regarding a family history of atopy and the progression of atopy in the child. It is also important to identify the specific triggers of allergic rhinitis, because one of the keys to successful management is the avoidance of triggers. A tripartite treatment strategy that embraces environmental control, immunotherapy, and pharmacologic treatment is the most comprehensive approach. Immunotherapy has come to be viewed as potentially prophylactic, capable of altering the course of allergic rhinitis. The most recent guidelines for the management of allergic rhinitis issued by the WHO recommend a tiered approach that integrates diagnosis and treatment, in which allergic rhinitis is subclassified both by frequency, as either intermittent or persistent, and by severity, as either mild or moderate to severe. Oral or topical antihistamines and intranasal corticosteroids are the mainstay of pharmacologic therapy for allergic rhinitis, depending upon its severity, and several agents have been approved for use in children aged 5 years old and younger.
Collapse
Affiliation(s)
- William E Berger
- Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA.
| |
Collapse
|
8
|
Abstract
PURPOSE OF REVIEW Sublingual immunotherapy is now officially accepted as a viable alternative to the traditional subcutaneous route, and it is widely used especially in European countries. Despite the large amount of experimental evidence on the safety and efficacy of the method, some concerns still exist, and several aspects need to be clarified: magnitude of the efficacy, adherence, long-lasting effect and others. Recently published studies have provided answers to some of these points. RECENT FINDINGS The most recent studies have shown that sublingual immunotherapy exerts a long-lasting effect up to 5 years after discontinuation and that it is able to prevent the onset of new sensitizations. Moreover, when systematically assessed, the adherence to treatment is quite satisfactory, despite the treatment being self-administered. In addition, evidence has been provided that sublingual immunotherapy is effective in treating allergic conjunctivitis, and a metaanalysis has confirmed its efficacy in rhinitis. Moreover, some studies have addressed the possibility of simplifying the schedule of administration by shortening the build-up phase. SUMMARY More and more new data on sublingual immunotherapy are rapidly appearing in the international literature. These data confirm the clinical value of this treatment and show that it is comparable to subcutaneous immunotherapy from several points of view.
Collapse
Affiliation(s)
- Giovanni Passalacqua
- Allergy & Respiratory Diseases, Department of Internal Medicine, University of Genoa, Genoa, Italy.
| | | | | |
Collapse
|
9
|
Marcella R, Croce A, Moretti A, Barbacane RC, Di Giocchino M, Conti P. Transcription and translation of the chemokines RANTES and MCP-1 in nasal polyps and mucosa in allergic and non-allergic rhinopathies. Immunol Lett 2003; 90:71-5. [PMID: 14687706 DOI: 10.1016/s0165-2478(03)00163-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The pathogenetic findings of rhinopathies show an increase in infiltrating cells including eosinophils. RANTES is a beta chemokine in which the cysteines are adjacent (C-C), and it attracts and activates eosinophil. We hypothesize that RANTES is locally produced within the nasal polyp microenvironment and is responsible for the inflammatory cell recruitment present in nasal polyposis. To test this hypothesis, we evaluated nasal polyps and mucosa from allergic and control, non-allergic patients for RANTES content. The relative levels of RANTES and MCP-1 protein in tissue homogenates were quantified using enzyme-linked immunosorbent assay technology, and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) tests for RANTES and MCP-1 mRNA expression were performed. The results indicate that RANTES expression and production increase in nasal mucosa (septal and turbinate portions) of allergic patients compared to the same mucosa in non-allergic patients. In allergic patients, RANTES levels of nasal polyp homogenates were nearly 12-fold higher than the RANTES levels in mucosa homogenate. In this study, we hypothesize that the particular anatomic structure and physiologic function of the turbinates are more involved in the pathogenesis of rhinitis and may undergo polypoid degeneration in allergic rhinitis than any other anatomical structure of the nose. Our data suggest that RANTES is more involved than MCP-1 in recruiting inflammatory cells in rhinological disease and may reflect the degree of local inflammation as consequence of the specific chemoattractant properties of RANTES. The level of RANTES in nasal polyps could be important in the development of the pathological state.
Collapse
Affiliation(s)
- Reale Marcella
- Department of Oncology and Neuroscience, Unit of Immunology and Experimental Medicine, School of Medicine, University of G D'Annunzio, Chieti, Italy
| | | | | | | | | | | |
Collapse
|
10
|
Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, Stefani E, Tierno E. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 2003; 16:73-9. [PMID: 12578735 DOI: 10.1177/039463200301600111] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
There is now an increasing body of evidence to support the practice of allergen-specific sublingual-swallow immunotherapy (SLIT) in the treatment of IgE-mediated respiratory allergies. Recent studies on traditional injection therapy have pointed out that this form of treatment is not only capable to decrease actual allergic symptoms, but may also have long-term clinical and preventive effects and may influence atopy natural history. In the year 2000, our group published a retrospective, multicenter study showing the efficacy and safety of SLIT in a survey of 302 patients. We now carried out a second study on the same patients, with the aim of investigating long-term and preventive effects of SLIT. Beside the well-known safety and efficacy of this treatment (80.8% of patients reported clinical benefits), SLIT proved also to elicit long term clinical effects: over a mean follow-up of 11.6 months after the end of treatment, 80.8% of patients still maintained the previously achieved benefits. During the follow-up period, only 1% of non-asthma patients reported an onset of respiratory symptoms, and only 9.6% of patients undergoing new skin tests showed new sensitizations. All the clinical benefits were strongly linked to the length of treatment: patients with long-lasting benefits were treated for a mean length of 29.1 months, while patients showing a return to pre-SLIT condition were treated for a mean 13.3 months. SLIT can obtain long-term and preventive effects so far attributed to injection immunotherapy.
Collapse
Affiliation(s)
- E Madonini
- Villa Marelli Institute, Respiratory Allergy Dept., Ospedale Niguarda Cà Granda, Milan, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Frydas S, Madhappan B, Kempuraj D. Some aspects of Parasitology and Immunology in general Medicine. Int J Immunopathol Pharmacol 2002; 15:165-170. [PMID: 12575916 DOI: 10.1177/039463200201500302] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
The objective of these studies is to review the role of some parasites and their components in inflammation, allergy and immune system. We also report recent results published by others group as well as our own.
Collapse
Affiliation(s)
- S. Frydas
- Parasitology Dept. Veterinary Faculty, Aristotelian University of Thessaloniki, Greece
| | | | | |
Collapse
|
12
|
Bruno G, Andreozzi P, Graf U, Tega F, Santangelo G, Barucco M, Bruno A, Bracchitta S. Cetirizine, a second-generation H1 antagonist, modulates Rantes and MCP-1 levels in allergic rhinitis. Int J Immunopathol Pharmacol 2002; 15:113-118. [PMID: 12590873 DOI: 10.1177/039463200201500206] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Chemokines and their receptors are involved in several allergic diseases. We measured RANTES and MCP-1 levels in sera of allergic rhinitis patients, and also we evaluated the effect of cetrizine, a second-generation H1 antagonist, on these chemoattractant proteins. 15 subjects were studied (10 males and 5 females; mean age: 26.7 years). They were suffering from perennial or seasonal allergic rhinitis induced by Dermatophagoides pteronyssinus (8 patients) or by grasses (7 patients). RANTES and MCP-1 serum levels were detected with an enzyme immunoassay before and after two weeks of treatment with 10 mg of cetirizine daily, and again after two weeks of washout. Baseline serum levels of RANTES and MCP-1 chemokines were significantly higher (p < 0.02 and p = 0.007, respectively) in allergic patients than in the healthy control group. Cetirizine resulted in a significant decrease in RANTES (p < 0.02) and MCP-1 (p = 0.003) versus baseline values. There is an increase in RANTES and MCP-1 in allergic rhinitis, which is counteracted by cetirizine.
Collapse
Affiliation(s)
- G. Bruno
- Allergologia e Immunologia Clinica, Dip Medicina Clinica, Università di Roma, Italy
| | | | | | | | | | | | | | | |
Collapse
|